We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Pill splitting

5 May 2011 By Robert Cyran

The Q1 results emphasize why the drugstore chain and pharma middleman units don’t belong together. They could be worth $13 bln more apart. With David Dorman stepping in to lead the board next week, the company has a chance to reconsider. He oversaw a similar carveup at Motorola.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)